Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 11, 2007, Pages 1293-1300

  Thurairajah, P H ^a   Thorburn, D ^a   Hubscher, S ^b   White, A ^b   Lai, W K ^a   O'Donnell, K ^a   Mutimer, D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; STEATOSIS; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TRANSAMINASES; TREATMENT OUTCOME;

EID: 34248531497     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03322.x     Document Type: Article

References (30)

1. WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999 6 : 35 47.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002 36 : S21 9.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 22 : 358.
4. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997 26 : 226 31.
5. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of INF therapy. Science 1998 282 : 103 7.
6. Cervoni JP, Degos F, Marcellin P, Erlinger S. Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. J Hepatol 1997 27 : 1113 6.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981 47 : 207 14.
8. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
9. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000 33 : 106 15.
10. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995 15 : 70 81.
11. Day C, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002 17 (Suppl. 3 S377 84.
12. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002 97 : 2714 24.
13. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002 282 : G193 9.
14. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002 36 : 1266 72.
15. Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004 53 : 420 4.
16. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000 343 : 1467 76.
17. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005 54 : 303 6.
18. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002 122 : 274 80.
19. Arnaud P. The interferons: pharmacology, mechanism of action, tolerance and side effects. Rev Med Interne 2002 23 (Suppl. 4 449s 58s.
20. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993 34 : S74 6.
21. Shapiro S, Gershtein V, Elias N, Zuckerman E, Salman N, Lahat N. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment. Clin Exp Immunol 1998 114 : 55 60.
22. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 : 75 85.
23. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004 40 : 484 90.
24. Mundt B, Wirth T, Zender L, et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005 54 : 1590 6.
25. Mundt B, Kuhnel F, Zender L, et al. Involvement of TRAIL and its receptor in viral hepatitis. FASEB J 2003 17 : 94 6.
26. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999 190 : 1155 64.
27. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999 189 : 1343 54.
28. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002 195 : 161 9.
29. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000 43 : 995 9.
30. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003 39 : 978 83.